RXRX240920C5000
- 1.53
- +0.03+2.00%
Recursion Pharmaceuticals Newsroom
Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10
Morgan Stanley analyst Vikram Purohit maintains $Recursion Pharmaceuticals(RXRX.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $11
Needham analyst Gil Blum maintains $Recursion Pharmaceuticals(RXRX.US)$ with a buy rating, and adjusts the target price from $16 to $11.According to TipRanks data, the analyst has a success rate of 38
Cathie Wood's ARK Sells CareDx, Buys Recursion Pharmaceuticals Stock
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
A Quick Look at Today's Ratings for Recursion Pharmaceuticals(RXRX.US), With a Forecast Between $8 to $14
On Sep 04, major Wall Street analysts update their ratings for $Recursion Pharmaceuticals(RXRX.US)$, with price targets ranging from $8 to $14.Morgan Stanley analyst Vikram Purohit maintains with a
Recursion Pharmaceuticals Maintains Buy Rating Amidst Modest Study Results and Strong Financial Position
Hold Rating on Recursion Pharmaceuticals Amidst Lukewarm Phase 2 Results and AI Platform Validation Concerns
Express News | Recursion Pharmaceuticals Shares Rise 2% Premarket After Sliding to Over Nine-Month Lows on Tue
Jefferies Maintains Hold on Recursion Pharmaceuticals, Lowers Price Target to $6
Recursion Pharmaceuticals Analyst Ratings
Leerink Partners Maintains Market Perform on Recursion Pharmaceuticals, Lowers Price Target to $8
Recursion Pharmaceuticals Shares Are Trading Lower. The Company Announced Top-line Results of the SYCAMORE Trial for REC-994 in Symptomatic CCM Patients.
Express News | Recursion Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $8 From $9
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10
Morgan Stanley analyst Vikram Purohit maintains $Recursion Pharmaceuticals(RXRX.US)$ with a hold rating, and adjusts the target price from $11 to $10.According to TipRanks data, the analyst has a
Express News | Recursion Pharmaceuticals Falls 10% Premarket; Co Says Blood Vessel Disorder Drug Meets Main Goal in Mid-Stage Study
Express News | Recursion Pharmaceuticals Inc - Meeting With FDA Anticipated to Discuss Additional Clinical Study
Express News | Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (Ccm), Has Met Its Primary Endpoint of Safety and Tolerability
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), Has Met Its Primary Endpoint of Safety and Tolerability
Recursion Pharmaceuticals (RXRX) Gets a Hold From Morgan Stanley